Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

Published:2018-01 Issue: Volume:11 Page:175628641879110
ISSN:1756-2864
Container-title:Therapeutic Advances in Neurological Disorders
language:en
Short-container-title:Ther Adv Neurol Disord

Author:

Diem Lara¹,Nedeltchev Krassen¹²,Kahles Timo¹,Achtnichts Lutz¹,Findling Oliver³

Affiliation:

1. Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland

2. Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland

3. Department of Neurology, Cantonal Hospital Aarau, Tellstrasse, Aarau 5000, Switzerland

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology,Pharmacology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1756286418791103

Reference32 articles.

1. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

2. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

3. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

4. Tysabri® (natalizumab) safety update, https://medinfo.biogen.com (2017, accessed 8 August 2017).

5. Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: an exploratory single-center study;Frontiers in Neuroscience;2023-09-14

2. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-02

3. Self‐injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real‐world cohort;Acta Neurologica Scandinavica;2022-01-19

4. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis–A systematic review and network meta-analysis;Multiple Sclerosis and Related Disorders;2021-04

5. Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?;Drug Discovery Today;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3